<DOC>
	<DOCNO>NCT02673164</DOCNO>
	<brief_summary>The aim SCIENCE study , international multicentre double-blind placebo-controlled study , investigate efficacy direct intra-myocardial injection 100 mio . allogeneic Cardiology Stem Cell Centre_adipose derive stem cell ( CSCC_ASCs ) patient reduce leave ventricular Ejection Fraction ( EF ) ( ≤45 % ) heart failure .</brief_summary>
	<brief_title>Stem Cell Therapy IschEmic Non-treatable Cardiac Disease</brief_title>
	<detailed_description>The aim SCIENCE study , international multicentre double-blind placebo-controlled study , investigate efficacy direct intra-myocardial injection 100 mio . allogeneic Cardiology Stem Cell Centre_adipose derive stem cell ( CSCC_ASCs ) patient reduce leave ventricular EF ( ≤45 % ) heart failure . The primary objective investigate regenerative capacity direct intra-myocardial injection 100 mio . allogeneic CSCC_ASCs patient reduce left ventricular EF ( ≤45 % ) heart failure double-blind placebo-controlled design . A total 138 patient enrol study treat 2:1 randomization either CSCC_ASC placebo ( saline ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<criteria>1 . 30 80 year age 2 . Signed informed consent 3 . Chronic stable ischemic heart disease 4 . Symptomatic heart failure New York Heart Association ( NYHA ) class IIIII 5 . EF ≤ 45 % echocardiography , Computerized Tomography ( CT ) Magnetic Resonances Imaging ( MRI ) scan 6 . Plasma NTproBNP &gt; 300 pg/ml ( &gt; 35 pmol/L ) 7 . Maximal tolerable heart failure medication 8 . Heart failure medication unchanged two month prior inclusion . Changes diuretic accept . 9 . No option percutaneous coronary intervention ( PCI ) coronary artery bypass graft ( CABG ) 10 . Patients PCI CABG within six month inclusion must new coronary angiography le one month inclusion least four month intervention rule early restenosis 11 . Patients include three month implantation cardiac resynchronisation therapy device ( CRTD ) 1 month ICD unit 1 . Heart Failure ( NYHA class I IV ) 2 . Acute coronary syndrome acute reversible elevation CKMB troponins , stroke transitory cerebral ischemia within six week inclusion . Constant elevate troponin due renal failure , heart failure etc . exclude patient . 3 . Other revascularisation treatment within four month treatment 4 . If clinically indicate patient coronary angiography inclusion 5 . Moderate severe aortic stenosis ( valve area &lt; 1.3 cm2 ) valvular disease option surgery interventional therapy . 6 . Aortic valve replacement artificial heart valve . However , transseptal treatment approach consider patient . 7 . If patient expect candidate MitraClip therapy mitral regurgitation 12 month followup period . 8 . Diminished functional capacity reason : obstructive pulmonary disease ( COPD ) force expiratory volume ( FEV ) &lt; 1 L/min , moderate severe claudication morbid obesity 9 . Clinical significant anaemia ( haemoglobin &lt; 6 mmol/L ) , leukopenia ( leucocytes &lt; 2 109/L ) , leucocytosis ( leucocytes &gt; 14 109/L ) thrombocytopenia ( thrombocytes &lt; 50 109/L ) 10 . Reduced kidney function ( estimate Glomerular Filtration Rate ( eGFR ) &lt; 30 ml/min ) 11 . Left ventricular thrombus 12 . Anticoagulation treatment pause cell injection . Patients continue platelet inhibitor treatment 13 . Patients reduce immune response know anti‐HLA ( human leukocyte antigen ) antibodies 14 . History malignant disease within five year inclusion suspect malignity except treated skin cancer melanoma 15 . Pregnant woman 16 . Other experimental treatment within four week baseline test 17 . Participation another intervention trial 18 . Life expectancy less one year 19 . Known hypersensitivity Dimethyl sulfoxide ( DMSO ) , penicillin streptomycin</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>stem cell</keyword>
	<keyword>adipose derived stem cell</keyword>
	<keyword>Stem cell therapy</keyword>
	<keyword>ischemic heart disease</keyword>
</DOC>